Bcl-2 targeted-therapy for the treatment of head and neck squamous cell carcinoma

Recent Patents on Anti-Cancer Drug Discovery

Volumn 6, Issue 1, 2011, Pages 45-57

  dos Santos, Lucas V ^a   Carvalho, André L ^a  

^a BARRETOS CANCER HOSPITAL   (Brazil)

Author keywords

Anticancer drugs; Apoptosis; Bcl 2 family proteins; Head and neck cancer; Patents; Targeted therapy

Indexed keywords

2 AMINO 6 BROMO 4 (1 CYANO 2 ETHOXY 2 OXOETHYL) 4H CHROMENE 3 CARBOXYLIC ACID ETHYL ESTER; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; 6 3139; ACTIMYCIN A; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BH3 PROTEIN; CHELERYTHRINE; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPIGALLOCATECHIN GALLATE; ERLOTINIB; ETOPOSIDE; GOSSYPOL; HARMINE; OBATOCLAX; OBLIMERSEN; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN BCL XL INHIBITOR; TW 37; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CELL PROLIFERATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG TARGETING; GENE OVEREXPRESSION; HEAD AND NECK CARCINOMA; HUMAN; PATENT; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; SQUAMOUS CELL CARCINOMA; SYSTEMIC THERAPY;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA; HEAD AND NECK NEOPLASMS; HUMANS; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; NEOPLASMS, SQUAMOUS CELL; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION;

EID: 78650939866     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489211793980042     Document Type: Article

References (229)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-49.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94: 153-6.
3. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2: 533-43.
4. Marur S, Forastiere AA. Head and neck cancer: Changing epidemiology, diagnosis, and treatment. Mayo Clin Proc 2008; 83: 489-501.
5. Coleman MP, Esteve J, Damiecki P, Arslan A, Renard H. Trends in cancer incidence and mortality. IARC Sci Publ 1993: 1-806.
6. Carvalho AL, Nishimoto IN, Califano JA, Kowalski LP. Trends in incidence and prognosis for head and neck cancer in the United States: A site-specific analysis of the SEER database. Int J Cancer 2005; 114: 806-16.
7. Posner M. Options in the Treatment of Head and Neck Cancer. Manhasset, NY: CMPMedica. The Oncology Group 2006.
8. Hitt R, Grau J, Lopez-Pousa A, Berrocal A, Giron GC, Irigoyen A, et al. Final results of a randomized phase III trial comparing induction chemotherapy with cisplatin/5-FU or docetaxel/ cisplatin/5-FU follow by chemoradiotherapy (CRT) versus CRT alone as first-line treatment of unresectable locally advanced head and neck cancer (LAHNC). J Clin Oncol 2009; 27: abstr 6009.
9. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359: 1116-27.
10. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-78.
11. Korsmeyer SJ. Regulators of cell death. Trends Genet 1995; 11: 101-5.
12. Loro LL, Vintermyr OK, Johannessen AC. Cell death regulation in oral squamous cell carcinoma: Methodological considerations and clinical significance. J Oral Pathol Med 2003; 32: 125-38.
13. Taylor RC, Cullen SP, Martin SJ. Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol 2008; 9: 231-41.
14. Hotchkiss RS, Strasser A, McDunn JE, Swanson PE. Cell death. N Engl J Med 2009; 361: 1570-83.
15. Adams JM, Cory S. Bcl-2-regulated apoptosis: Mechanism and therapeutic potential. Curr Opin Immunol 2007; 19: 488-96.
16. Youle RJ, Strasser A. The Bcl-2 protein family: Opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008; 9: 47-59.
17. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997; 91: 479-89.
18. Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000; 102: 33-42.
19. Goldstein JC, Munoz-Pinedo C, Ricci JE, Adams SR, Kelekar A, Schuler M, et al. Cytochrome c is released in a single step during apoptosis. Cell Death Differ 2005; 12: 453-62.
20. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
21. McDonnell TJ, Deane N, Platt FM, Nunez G, Jaeger U, McKearn JP, et al. Bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 1989; 57: 79-88.
22. Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988; 335: 440-2.
23. Willis SN, Adams JM. Life in the balance: how BH3-only proteins induce apoptosis. Curr Opin Cell Biol 2005; 17: 617-25.
24. Cory S, Huang DC, Adams JM. The Bcl-2 family: Roles in cell survival and oncogenesis. Oncogene 2003; 22: 8590-607.
25. Danial NN, Korsmeyer SJ. Cell death: Critical control points. Cell 2004; 116: 205-19.
26. Green DR. Apoptotic pathways: Ten minutes to dead. Cell 2005; 121: 671-4.
27. Opferman JT, Korsmeyer SJ. Apoptosis in the development and maintenance of the immune system. Nat Immunol 2003; 4: 410-5.
28. Chittenden T, Flemington C, Houghton AB, Ebb RG, Gallo GJ, Elangovan B, et al. A conserved domain in Bak, distinct from BH1 and BH2, mediates cell death and protein binding functions. EMBO J 1995; 14: 5589-96.
29. Yin XM, Oltvai ZN, Korsmeyer SJ. BH1 and BH2 domains of Bcl- 2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 1994; 369: 321-3.
30. Cheng EH, Wei MC, Weiler S, Flavell RA, Mak TW, Lindsten T, et al. Bcl-2, Bcl-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell 2001; 8: 705-11.
31. Lindsten T, Ross AJ, King A, Zong WX, Rathmell JC, Shiels HA, et al. The combined functions of proapoptotic Bcl-2 family members Bak and Bax are essential for normal development of multiple tissues. Mol Cell 2000; 6: 1389-99.
32. Puthalakath H, Strasser A. Keeping killers on a tight leash: Transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins. Cell Death Differ 2002; 9: 505-12.
33. Zong WX, Lindsten T, Ross AJ, MacGregor GR, Thompson CB. BH3-only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak. Genes Dev 2001; 15: 1481-6.
34. Day CL, Chen L, Richardson SJ, Harrison PJ, Huang DC, Hinds MG. Solution structure of prosurvival Mcl-1 and characterization of its binding by proapoptotic BH3-only ligands. J Biol Chem 2005; 280: 4738-44.
35. Liu X, Dai S, Zhu Y, Marrack P, Kappler JW. The structure of a Bcl-xL/Bim fragment complex: Implications for Bim function. Immunity 2003; 19: 341-52.
36. Petros AM, Nettesheim DG, Wang Y, Olejniczak ET, Meadows RP, Mack J, et al. Rationale for Bcl-xL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies. Protein Sci 2000; 9: 2528-34.
37. Sattler M, Liang H, Nettesheim D, Meadows RP, Harlan JE, Eberstadt M, et al. Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science 1997; 275: 983-6.
38. Suzuki M, Youle RJ, Tjandra N. Structure of Bax: Coregulation of dimer formation and intracellular localization. Cell 2000; 103: 645-54.
39. Rathmell JC, Lindsten T, Zong WX, Cinalli RM, Thompson CB. Deficiency in Bak and Bax perturbs thymic selection and lymphoid homeostasis. Nat Immunol 2002; 3: 932-9.
40. Oh KJ, Barbuto S, Pitter K, Morash J, Walensky LD, Korsmeyer SJ. A membrane-targeted BID Bcl-2 homology 3 peptide is sufficient for high potency activation of BAX in vitro. J Biol Chem 2006; 281: 36999-7008.
41. Skommer J, Wlodkowic D, Deptala A. Larger than life: Mitochondria and the Bcl-2 family. Leuk Res 2007; 31: 277-86.
42. Huang DC, Strasser A. BH3-Only proteins-essential initiators of apoptotic cell death. Cell 2000; 103: 839-42.
43. Chalah A, Khosravi-Far R. The mitochondrial death pathway. Adv Exp Med Biol 2008; 615: 25-45.
44. Rong Y, Distelhorst CW. Bcl-2 protein family members: Versatile regulators of calcium signaling in cell survival and apoptosis. Annu Rev Physiol 2008; 70: 73-91.
45. Suen DF, Norris KL, Youle RJ. Mitochondrial dynamics and apoptosis. Genes Dev 2008; 22: 1577-90.
46. Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ, et al. Proapoptotic BAX and BAK: A requisite gateway to mitochondrial dysfunction and death. Science 2001; 292: 727-30.
47. Mikhailov V, Mikhailova M, Degenhardt K, Venkatachalam MA, White E, Saikumar P. Association of Bax and Bak homo-oligomers in mitochondria. Bax requirement for Bak reorganization and cytochrome c release. J Biol Chem 2003; 278: 5367-76.
48. Sundararajan R, Cuconati A, Nelson D, White E. Tumor necrosis factor-alpha induces Bax-Bak interaction and apoptosis, which is inhibited by adenovirus E1B 19K. J Biol Chem 2001; 276: 45120-7.
49. Hamasaki A, Sendo F, Nakayama K, Ishida N, Negishi I, Hatakeyama S. Accelerated neutrophil apoptosis in mice lacking A1-a, a subtype of the Bcl-2-related A1 gene. J Exp Med 1998; 188: 1985-92.
50. Kamada S, Shimono A, Shinto Y, Tsujimura T, Takahashi T, Noda T, et al. Bcl-2 deficiency in mice leads to pleiotropic abnormalities: accelerated lymphoid cell death in thymus and spleen, polycystic kidney, hair hypopigmentation, and distorted small intestine. Cancer Res 1995; 55: 354-9.
51. Motoyama N, Kimura T, Takahashi T, Watanabe T, Nakano T. Bcl-x prevents apoptotic cell death of both primitive and definitive erythrocytes at the end of maturation. J Exp Med 1999; 189: 1691-8.
52. Motoyama N, Wang F, Roth KA, Sawa H, Nakayama K, Negishi I, et al. Massive cell death of immature hematopoietic cells and neurons in Bcl-x-deficient mice. Science 1995; 267: 1506-10.
53. Nakayama K, Negishi I, Kuida K, Sawa H, Loh DY. Targeted disruption of Bcl-2 alpha beta in mice: Occurrence of gray hair, polycystic kidney disease, and lymphocytopenia. Proc Natl Acad Sci USA 1994; 91: 3700-4.
54. Opferman JT, Iwasaki H, Ong CC, Suh H, Mizuno S, Akashi K, et al. Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. Science 2005; 307: 1101-4.
55. Opferman JT, Letai A, Beard C, Sorcinelli MD, Ong CC, Korsmeyer SJ. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature 2003; 426: 671-6.
56. Print CG, Loveland KL, Gibson L, Meehan T, Stylianou A, Wreford N, et al. Apoptosis regulator Bcl-w is essential for spermatogenesis but appears otherwise redundant. Proc Natl Acad Sci USA 1998; 95: 12424-31.
57. Rinkenberger JL, Horning S, Klocke B, Roth K, Korsmeyer SJ. Mcl-1 deficiency results in peri-implantation embryonic lethality. Genes Dev 2000; 14: 23-7.
58. Ross AJ, Waymire KG, Moss JE, Parlow AF, Skinner MK, Russell LD, et al. Testicular degeneration in Bclw-deficient mice. Nat Genet 1998; 18: 251-6.
59. Veis DJ, Sorenson CM, Shutter JR, Korsmeyer SJ. Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell 1993; 75: 229-40.
60. Wagner KU, Claudio E, Rucker EB, 3rd, Riedlinger G, Broussard C, Schwartzberg PL, et al. Conditional deletion of the Bcl-x gene from erythroid cells results in hemolytic anemia and profound splenomegaly. Development 2000; 127: 4949-58.
61. Mikhailov V, Mikhailova M, Pulkrabek DJ, Dong Z, Venkata-chalam MA, Saikumar P. Bcl-2 prevents Bax oligomerization in the mitochondrial outer membrane. J Biol Chem 2001; 276: 18361-74.
62. Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA, et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic Bcl-2 family members. Cancer Cell 2006; 9: 351-65.
63. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG, et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3- only ligands allows complementary apoptotic function. Mol Cell 2005; 17: 393-403.
64. Green DR. At the gates of death. Cancer Cell 2006; 9: 328-30.
65. Baffy G, Miyashita T, Williamson JR, Reed JC. Apoptosis induced by withdrawal of interleukin-3 (IL-3) from an IL-3-dependent hematopoietic cell line is associated with repartitioning of intracellular calcium and is blocked by enforced Bcl-2 oncoprotein production. J Biol Chem 1993; 268: 6511-9.
66. Lam M, Dubyak G, Chen L, Nunez G, Miesfeld RL, Distelhorst CW. Evidence that Bcl-2 represses apoptosis by regulating endoplasmic reticulum-associated Ca2+ fluxes. Proc Natl Acad Sci USA 1994; 91: 6569-73.
67. Kuwana T, Bouchier-Hayes L, Chipuk JE, Bonzon C, Sullivan BA, Green DR, et al. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell 2005; 17: 525-35.
68. Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2002; 2: 183-92.
69. Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI, et al. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl- 2, until displaced by BH3-only proteins. Genes Dev 2005; 19: 1294-305.
70. Bouillet P, Metcalf D, Huang DC, Tarlinton DM, Kay TW, Kontgen F, et al. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 1999; 286: 1735-8.
71. Bouillet P, Purton JF, Godfrey DI, Zhang LC, Coultas L, Puthalakath H, et al. BH3-only Bcl-2 family member Bim is required for apoptosis of autoreactive thymocytes. Nature 2002; 415: 922-6.
72. Enders A, Bouillet P, Puthalakath H, Xu Y, Tarlinton DM, Strasser A. Loss of the pro-apoptotic BH3-only Bcl-2 family member Bim inhibits BCR stimulation-induced apoptosis and deletion of autoreactive B cells. J Exp Med 2003; 198: 1119-26.
73. Labi V, Grespi F, Baumgartner F, Villunger A. Targeting the Bcl- 2-regulated apoptosis pathway by BH3 mimetics: A breakthrough in anticancer therapy? Cell Death Differ 2008; 15: 977-87.
74. Willis SN, Fletcher JI, Kaufmann T, van Delft MF, Chen L, Czabotar PE, et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 2007; 315: 856-9.
75. Chun KH, Lee HY, Hassan K, Khuri F, Hong WK, Lotan R. Implication of protein kinase B/Akt and Bcl-2/Bcl-XL suppression by the farnesyl transferase inhibitor SCH66336 in apoptosis induction in squamous carcinoma cells. Cancer Res 2003; 63: 4796-800.
76. Li D, Ueta E, Kimura T, Yamamoto T, Osaki T. Reactive oxygen species (ROS) control the expression of Bcl-2 family proteins by regulating their phosphorylation and ubiquitination. Cancer Sci 2004; 95: 644-50.
77. Lee TL, Yeh J, Friedman J, Yan B, Yang X, Yeh NT, et al. A signal network involving coactivated NF-kappaB and STAT3 and altered p53 modulates Bax/Bcl-XL expression and promotes cell survival of head and neck squamous cell carcinomas. Int J Cancer 2008; 122: 1987-98.
78. Gallo O, Boddi V, Calzolari A, Simonetti L, Trovati M, Bianchi S. Bcl-2 protein expression correlates with recurrence and survival in early stage head and neck cancer treated by radiotherapy. Clin Cancer Res 1996; 2: 261-7.
79. Badaracco G, Venuti A, Bartolazzi A, Morello R, Marzetti F, Marcante ML. Overexpression of p53 and Bcl-2 proteins and the presence of HPV infection are independent events in head and neck cancer. J Oral Pathol Med 2000; 29: 173-9.
80. Oliveira MC, Soares RC, Pinto LP, Souza LB, Medeiros SR, Costa Ade L. High-risk human papillomavirus (HPV) is not associated with p53 and Bcl-2 expression in oral squamous cell carcinomas. Auris Nasus Larynx 2009; 36: 450-6.
81. Drenning SD, Marcovitch AJ, Johnson DE, Melhem MF, Tweardy DJ, Grandis JR. Bcl-2 but not Bax expression is associated with apoptosis in normal and transformed squamous epithelium. Clin Cancer Res 1998; 4: 2913-21.
82. Yao L, Iwai M, Furuta I. Correlations of Bcl-2 and p53 expression with the clinicopathological features in tongue squamous cell carcinomas. Oral Oncol 1999; 35: 56-62.
83. Pignataro L, Carboni N, Pagliari AV, Capaccio P, Ottaviani F, Pruneri G. Bcl-2 expression is related to poor differentiation and advanced clinical stage in laryngeal squamous cell carcinoma. J Chemother 1997; 9: 115-6.
84. Whisler LC, Wood NB, Caldarelli DD, Hutchinson JC, Panje WR, Friedman M, et al. Regulators of proliferation and apoptosis in carcinoma of the larynx. Laryngoscope 1998; 108: 630-8.
85. Jordan RC, Catzavelos GC, Barrett AW, Speight PM. Differential expression of Bcl-2 and Bax in squamous cell carcinomas of the oral cavity. Eur J Cancer B Oral Oncol 1996; 32B: 394-400.
86. Singh BB, Chandler FW, Jr., Whitaker SB, Forbes-Nelson AE. Immunohistochemical evaluation of Bcl-2 oncoprotein in oral dysplasia and carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998; 85: 692-8.
87. Pruneri G, Pignataro L, Carboni N, Ronchetti D, Cesana BM, Ottaviani A, et al. Clinical relevance of p53 and Bcl-2 protein over-expression in laryngeal squamous-cell carcinoma. Int J Cancer 1998; 79: 263-8.
88. Jackel MC, Dorudian MA, Marx D, Brinck U, Schauer A, Steiner W. Spontaneous apoptosis in laryngeal squamous cell carcinoma is independent of Bcl-2 and Bax protein expression. Cancer 1999; 85: 591-9.
89. Wilson GD, Saunders MI, Dische S, Richman PI, Daley FM, Bentzen SM. Bcl-2 expression in head and neck cancer: An enigmatic prognostic marker. Int J Radiat Oncol Biol Phys 2001; 49: 435-41.
90. Shindoh M, Adachi M, Higashino F, Yasuda M, Hida K, Nishioka T, et al. BAG-1 expression correlates highly with the malignant potential in early lesions (T1 and T2) of oral squamous cell carcinoma. Oral Oncol 2000; 36: 444-9.
91. Yamauchi H, Adachi M, Sakata K, Hareyama M, Satoh M, Himi T, et al. Nuclear BAG-1 localization and the risk of recurrence after radiation therapy in laryngeal carcinomas. Cancer Lett 2001; 165: 103-10.
92. Hague A, Packham G, Huntley S, Shefford K, Eveson JW. Deregulated Bag-1 protein expression in human oral squamous cell carcinomas and lymph node metastases. J Pathol 2002; 197: 60-71.
93. Xie X, Clausen OP, Boysen M. Bag-1 expression as a prognostic factor in tongue squamous cell carcinomas. Laryngoscope 2004; 114: 1785-90.
94. Dawson CW, Eliopoulos AG, Dawson J, Young LS. BHRF1, a viral homologue of the Bcl-2 oncogene, disturbs epithelial cell differentiation. Oncogene 1995; 10: 69-77.
95. Gibson SA, Pellenz C, Hutchison RE, Davey FR, Shillitoe EJ. Induction of apoptosis in oral cancer cells by an anti-Bcl-2 ribozyme delivered by an adenovirus vector. Clin Cancer Res 2000; 6: 213-22.
96. Andrews GA, Xi S, Pomerantz RG, Lin CJ, Gooding WE, Wentzel AL, et al. Mutation of p53 in head and neck squamous cell carcinoma correlates with Bcl-2 expression and increased susceptibility to cisplatin-induced apoptosis. Head Neck 2004; 26: 870-7.
97. Crowe DL, Sinha UK. p53 apoptotic response to DNA damage dependent on Bcl-2 but not bax in head and neck squamous cell carcinoma lines. Head Neck 2006; 28: 15-23.
98. Aggarwal S, Takada Y, Singh S, Myers JN, Aggarwal BB. Inhibition of growth and survival of human head and neck squamous cell carcinoma cells by curcumin via modulation of nuclear factor-kappaB signaling. Int J Cancer 2004; 111: 679-92.
99. Nishimura A. Changes in Bcl-2 and Bax expression in rat tongue during 4-nitroquinoline 1-oxide-induced carcinogenesis. J Dent Res 1999; 78: 1264-9.
100. Hussein MR. Alterations of p53 and Bcl-2 protein expression in the laryngeal intraepithelial neoplasia. Cancer Biol Ther 2005; 4: 213-7.
101. Derka S, Vairaktaris E, Papakosta V, Vassiliou S, Acil Y, Vylliotis A, et al. Cell proliferation and apoptosis culminate in early stages of oral oncogenesis. Oral Oncol 2006; 42: 540-50.
102. Salo A, Servomaa K, Kiuru A, Pulkkinen J, Grenman R, Pekkola- Heino K, et al. The Bcl-2 gene status of human head and neck cancer cell lines. Acta Otolaryngol Suppl 1997; 529: 233-6.
103. Mese H, Sasaki A, Alcalde RE, Nakayama S, Matsumura T. Regulation of apoptosis reduction in the cisplatin-resistant A431 cell line by Bcl-2 and CPP32. Chemotherapy 2000; 46: 69-76.
104. Mirjolet JF, Barberi-Heyob M, Didelot C, Peyrat JP, Abecassis J, Millon R, et al. Bcl-2/Bax protein ratio predicts 5-fluorouracil sensitivity independently of p53 status. Br J Cancer 2000; 83: 1380-6.
105. Noutomi T, Chiba H, Itoh M, Toyota H, Mizuguchi J. Bcl-x(L) confers multi-drug resistance in several squamous cell carcinoma cell lines. Oral Oncol 2002; 38: 41-8.
106. Zhu B, Liu GT, Zhao YM, Wu RS, Strada SJ. Chemosensitizing multiple drug resistance of human carcinoma by Bicyclol involves attenuated p-glycoprotein, GST-P and Bcl-2. Cancer Biol Ther 2006; 5: 536-43.
107. Michaud WA, Nichols AC, Mroz EA, Faquin WC, Clark JR, Begum S, et al. Bcl-2 blocks cisplatin-induced apoptosis and predicts poor outcome following chemoradiation treatment in advanced oropharyngeal squamous cell carcinoma. Clin Cancer Res 2009; 15: 1645-54.
108. Sawada S, Mese H, Sasaki A, Yoshioka N, Matsumura T. Combination chemotherapy of paclitaxel and cisplatin induces apoptosis with Bcl-2 phosphorylation in a cisplatin-resistant human epidermoid carcinoma cell line. Cancer Chemother Pharmacol 2003; 51: 505-11.
109. Nor JE, Christensen J, Liu J, Peters M, Mooney DJ, Strieter RM, et al. Up-Regulation of Bcl-2 in microvascular endothelial cells enhances intratumoral angiogenesis and accelerates tumor growth. Cancer Res 2001; 61: 2183-8.
110. Kaneko T, Zhang Z, Mantellini MG, Karl E, Zeitlin B, Verhaegen M, et al. Bcl-2 orchestrates a cross-talk between endothelial and tumor cells that promotes tumor growth. Cancer Res 2007; 67: 9685-93.
111. Kumar P, Coltas IK, Kumar B, Chepeha DB, Bradford CR, Polverini PJ. Bcl-2 protects endothelial cells against gamma-radiation via a Raf-MEK-ERK-survivin signaling pathway that is independent of cytochrome c release. Cancer Res 2007; 67: 1193-202.
112. Miyazawa M, Dong Z, Zhang Z, Neiva KG, Cordeiro MM, Oliveira DT, et al. Effect of PTK/ZK on the angiogenic switch in head and neck tumors. J Dent Res 2008; 87: 1166-71.
113. Xie YE, Tang EJ, Zhang DR, Ren BX. Down-regulation of Bcl-XL by RNA interference suppresses cell growth and induces apoptosis in human esophageal cancer cells. World J Gastroenterol 2006; 12: 7472-7.
114. Chen SM, Wang Y, Xiao BK, Tao ZZ. Effect of blocking VEGF, hTERT and Bcl-xl by multiple shRNA expression vectors on the human laryngeal squamous carcinoma xenograft in nude mice. Cancer Biol Ther 2008; 7: 734-9.
115. Schoop RA, Kooistra K, Baatenburg De Jong RJ, Noteborn MH. Bcl-xL inhibits p53- but not apoptin-induced apoptosis in head and neck squamous cell carcinoma cell line. Int J Cancer 2004; 109: 38-42.
116. Otani Y, Tsutsumi K, Kuwahara D, Oyake D, Ohta T, Nishikawa H, et al. Sensitization of head and neck squamous cell carcinoma cells to Fas-mediated apoptosis by the inhibition of Bcl-X(L) expression. Auris Nasus Larynx 2003; 30 Suppl: S79-84.
117. Itoh M, Noutomi T, Chiba H, Mizuguchi J. BcI-xL antisense treatment sensitizes Bcl-xL-overexpressing squamous cell carcinoma cells to carboplatin. Oral Oncol 2002; 38: 752-6.
118. Bauer JA, Kumar B, Cordell KG, Prince ME, Tran HH, Wolf GT, et al. Targeting apoptosis to overcome cisplatin resistance: A translational study in head and neck cancer. Int J Radiat Oncol Biol Phys 2007; 69: S106-8.
119. Wang Y, Tao ZZ, Chen SM, Xiao BK, Zhou XH, Liu JP. Application of combination of short hairpin RNA segments for silencing VEGF, TERT and Bcl-xl expression in laryngeal squamous carcinoma. Cancer Biol Ther 2008; 7: 896-901.
120. Li C, Li R, Grandis JR, Johnson DE. Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells. Mol Cancer Ther 2008; 7: 1647-55.
121. Wilson GD, Grover R, Richman PI, Daley FM, Saunders MI, Dische S. Bcl-2 expression correlates with favourable outcome in head and neck cancer treated by accelerated radiotherapy. Anticancer Res 1996; 16: 2403-8.
122. Spafford MF, Koeppe J, Pan Z, Archer PG, Meyers AD, Franklin WA. Correlation of tumor markers p53, Bcl-2, CD34, CD44H, CD44v6, and Ki-67 with survival and metastasis in laryngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 1996; 122: 627-32.
123. Nylander K, Schildt EB, Eriksson M, Roos G. PCNA, Ki-67, p53, Bcl-2 and prognosis in intraoral squamous cell carcinoma of the head and neck. Anal Cell Pathol 1997; 14: 101-10.
124. Veneroni S, Silvestrini R, Costa A, Salvatori P, Faranda A, Molinari R. Biological indicators of survival in patients treated by surgery for squamous cell carcinoma of the oral cavity and oropharynx. Oral Oncol 1997; 33: 408-13.
125. Jin YT, Kayser S, Kemp BL, Ordonez NG, Tucker SL, Clayman GL, et al. The prognostic significance of the biomarkers p21WAF1/CIP1, p53, and Bcl-2 in laryngeal squamous cell carcinoma. Cancer 1998; 82: 2159-65.
126. Pena JC, Thompson CB, Recant W, Vokes EE, Rudin CM. Bcl-xL and Bcl-2 expression in squamous cell carcinoma of the head and neck. Cancer 1999; 85: 164-70.
127. Aebersold DM, Kollar A, Beer KT, Laissue J, Greiner RH, Djonov V. Involvement of the hepatocyte growth factor/scatter factor receptor c-met and of Bcl-xL in the resistance of oropharyngeal cancer to ionizing radiation. Int J Cancer 2001; 96: 41-54.
128. Homma A, Furuta Y, Oridate N, Nakano Y, Yagi K, Nagahashi T, et al. Correlation of clinicopathological parameters and biological markers related to apoptosis and proliferative activity with a clinical outcome in squamous cell carcinoma of the larynx treated with concurrent chemoradiotherapy. Auris Nasus Larynx 2001; 28 Suppl: S87-94.
129. Fouret P, Temam S, Charlotte F, Lacau-St-Guily J. Tumour stage, node stage, p53 gene status, and Bcl-2 protein expression as predictors of tumour response to platin-fluorouracil chemotherapy in patients with squamous-cell carcinoma of the head and neck. Br J Cancer 2002; 87: 1390-5.
130. Sampaio-Goes FC, Oliveira DT, Dorta RG, Nonogaki S, Landman G, Nishimoto IN, et al. Expression of PCNA, p53, Bax, and Bcl-X in oral poorly differentiated and basaloid squamous cell carcinoma: relationships with prognosis. Head Neck 2005; 27: 982-9.
131. Gasparini G, Bevilacqua P, Bonoldi E, Testolin A, Galassi A, Verderio P, et al. Predictive and prognostic markers in a series of patients with head and neck squamous cell invasive carcinoma treated with concurrent chemoradiation therapy. Clin Cancer Res 1995; 1: 1375-83.
132. Friedman M, Grey P, Venkatesan TK, Bloch I, Chawla P, Caldarelli DD, et al. Prognostic significance of Bcl-2 expression in localized squamous cell carcinoma of the head and neck. Ann Otol Rhinol Laryngol 1997; 106: 445-50.
133. Hirvikoski P, Kumpulainen E, Virtaniemi J, Pirinen R, Salmi L, Halonen P, et al. Enhanced apoptosis correlates with poor survival in patients with laryngeal cancer but not with cell proliferation, bcl- 2 or p53 expression. Eur J Cancer 1999; 35: 231-7.
134. Condon LT, Ashman JN, Ell SR, Stafford ND, Greenman J, Cawkwell L. Overexpression of Bcl-2 in squamous cell carcinoma of the larynx: A marker of radioresistance. Int J Cancer 2002; 100: 472-5.
135. Georgiou A, Gomatos IP, Pararas NB, Giotakis J, Ferekidis E. Cell kinetics and apoptosis in laryngeal carcinoma patients. Ann Otol Rhinol Laryngol 2003; 112: 206-13.
136. Nix P, Cawkwell L, Patmore H, Greenman J, Stafford N. Bcl-2 expression predicts radiotherapy failure in laryngeal cancer. Br J Cancer 2005; 92: 2185-9.
137. Mannarini L, Bertino G, Morbini P, Villa C, Benazzo M. Markers of chemoradiation resistance in patients with locally advanced head and neck squamous cell carcinoma, treated by intra-arterial carboplatin and concurrent radiation. Acta Otorhinolaryngol Ital 2007; 27: 173-80.
138. Lehnerdt GF, Franz P, Bankfalvi A, Grehl S, Kelava A, Nuckel H, et al. The regulatory BCL2 promoter polymorphism (-938C>A) is associated with relapse and survival of patients with oropharyngeal squamous cell carcinoma. Ann Oncol 2009; 20: 1094-9.
139. Buffa FM, Bentzen SM, Daley FM, Dische S, Saunders MI, Richman PI, et al. Molecular marker profiles predict locoregional control of head and neck squamous cell carcinoma in a randomized trial of continuous hyperfractionated accelerated radiotherapy. Clin Cancer Res 2004; 10: 3745-54.
140. Trask DK, Wolf GT, Bradford CR, Fisher SG, Devaney K, Johnson M, et al. Expression of Bcl-2 family proteins in advanced laryngeal squamous cell carcinoma: Correlation with response to chemo-therapy and organ preservation. Laryngoscope 2002; 112: 638-44.
141. Roberg K, Jonsson AC, Grenman R, Norberg-Spaak L. Radiotherapy response in oral squamous carcinoma cell lines: Evaluation of apoptotic proteins as prognostic factors. Head Neck 2007; 29: 325-34.
142. Kumar B, Cordell KG, D'Silva N, Prince ME, Adams ME, Fisher SG, et al. Expression of p53 and Bcl-xL as predictive markers for larynx preservation in advanced laryngeal cancer. Arch Otolaryngol Head Neck Surg 2008; 134: 363-9.
143. Kumar B, Cordell KG, Lee JS, Worden FP, Prince ME, Tran HH, et al. EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 2008; 26: 3128-37.
144. Xie X, Clausen OP, De Angelis P, Boysen M. The prognostic value of spontaneous apoptosis, Bax, Bcl-2, and p53 in oral squamous cell carcinoma of the tongue. Cancer 1999; 86: 913-20.
145. Chen GG, Vlantis AC, Chak EC, Liu HC, Tong MC, van Hasselt CA. The expression of Bcl-2 family proteins and spontaneous apoptosis in laryngeal carcinomas. Oncol Res 2006; 16: 273-80.
146. Lavieille JP, Gazzeri S, Riva C, Reyt E, Brambilla C, Brambilla E. p53 mutations and p53, Waf-1, Bax and Bcl-2 expression in field cancerization of the head and neck. Anticancer Res 1998; 18: 4741-9.
147. Ito T, Fujieda S, Tsuzuki H, Sunaga H, Fan G, Sugimoto C, et al. Decreased expression of Bax is correlated with poor prognosis in oral and oropharyngeal carcinoma. Cancer Lett 1999; 140: 81-91.
148. Bandoh N, Hayashi T, Kishibe K, Takahara M, Imada M, Nonaka S, et al. Prognostic value of p53 mutations, bax, and spontaneous apoptosis in maxillary sinus squamous cell carcinoma. Cancer 2002; 94: 1968-80.
149. Fujieda S, Inuzuka M, Tanaka N, Sunaga H, Fan GK, Ito T, et al. Expression of p27 is associated with Bax expression and spontaneous apoptosis in oral and oropharyngeal carcinoma. Int J Cancer 1999; 84: 315-20.
150. Du J, Chen GG, Vlantis AC, Chan PK, Tsang RK, van Hasselt CA. Resistance to apoptosis of HPV 16-infected laryngeal cancer cells is associated with decreased Bak and increased Bcl-2 expression. Cancer Lett 2004; 205: 81-8.
151. Sugimoto C, Fujieda S, Seki M, Sunaga H, Fan GK, Tsuzuki H, et al. Apoptosis-promoting gene (bax) transfer potentiates sensitivity of squamous cell carcinoma to cisplatin in vitro and in vivo. Int J Cancer 1999; 82: 860-7.
152. Guo B, Yin MB, Toth K, Cao S, Azrak RG, Rustum YM. Dimerization of mitochondrial Bax is associated with increased drug response in Bax-transfected A253 cells. Oncol Res 1999; 11: 91-9.
153. Kawakami K, Tsukuda M, Mizuno H, Nishimura G, Ishii A, Hamajima K. Alteration of the Bcl-2/Bax status of head and neck cancer cell lines by chemotherapeutic agents. Anticancer Res 1999; 19: 3927-32.
154. Taguchi T, Kato Y, Baba Y, Nishimura G, Tanigaki Y, Horiuchi C, et al. Protein levels of p21, p27, cyclin E and Bax predict sensitivity to cisplatin and paclitaxel in head and neck squamous cell carcinomas. Oncol Rep 2004; 11: 421-6.
155. Takemura K, Noguchi M, Ogi K, Tokino T, Kubota H, Miyazaki A, et al. Enhanced Bax in oral SCC in relation to antitumor effects of chemotherapy. J Oral Pathol Med 2005; 34: 93-9.
156. Kim R, Inoue H, Toge T. Bax is an important determinant for radiation sensitivity in esophageal carcinoma cells. Int J Mol Med 2004; 14: 697-706.
157. Kato K, Kawashiri S, Yoshizawa K, Kitahara H, Yamamoto E. Apoptosis-associated markers and clinical outcome in human oral squamous cell carcinomas. J Oral Pathol Med 2008; 37: 364-71.
158. Subapriya R, Bhuvaneswari V, Nagini S. Ethanolic neem (Azadirachta indica) leaf extract induces apoptosis in the hamster buccal pouch carcinogenesis model by modulation of Bcl-2, Bim, caspase 8 and caspase 3. Asian Pac J Cancer Prev 2005; 6: 515-20.
159. Gillings AS, Balmanno K, Wiggins CM, Johnson M, Cook SJ. Apoptosis and autophagy: BIM as a mediator of tumour cell death in response to oncogene-targeted therapeutics. FEBS J 2009; 276: 6050-62.
160. Noda T, Iwai S, Hamada M, Fujita Y, Yura Y. Induction of apoptosis of detached oral squamous cell carcinoma cells by safingol. Possible role of Bim, focal adhesion kinase and endonuclease G. Apoptosis 2009; 14: 287-97.
161. Fribley AM, Evenchik B, Zeng Q, Park BK, Guan JY, Zhang H, et al. Proteasome inhibitor PS-341 induces apoptosis in cisplatin-resistant squamous cell carcinoma cells by induction of Noxa. J Biol Chem 2006; 281: 31440-7.
162. Sun Q, Sakaida T, Yue W, Gollin SM, Yu J. Chemosensitization of head and neck cancer cells by PUMA. Mol Cancer Ther 2007; 6: 3180-8.
163. Sun Q, Ming L, Thomas SM, Wang Y, Chen ZG, Ferris RL, et al. PUMA mediates EGFR tyrosine kinase inhibitor-induced apoptosis in head and neck cancer cells. Oncogene 2009; 28: 2348-57.
164. Zeitlin BD, Zeitlin IJ, Nor JE. Expanding circle of inhibition: small-molecule inhibitors of Bcl-2 as anticancer cell and antiangiogenic agents. J Clin Oncol 2008; 26: 4180-8.
165. Song JI, Grandis JR. STAT signaling in head and neck cancer. Oncogene 2000; 19: 2489-95.
166. Zhai, H., Cai, X. Bcl-2 inhibitors. WO2009036035 (2009).
167. Zhai D, Jin C, Satterthwait AC, Reed JC. Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins. Cell Death Differ 2006; 13: 1419-21.
168. Masuda M, Suzui M, Weinstein IB. Effects of epigallocatechin-3-gallate on growth, epidermal growth factor receptor signaling pathways, gene expression, and chemosensitivity in human head and neck squamous cell carcinoma cell lines. Clin Cancer Res 2001; 7: 4220-9.
169. Leone M, Zhai D, Sareth S, Kitada S, Reed JC, Pellecchia M. Cancer prevention by tea polyphenols is linked to their direct inhibition of antiapoptotic Bcl-2-family proteins. Cancer Res 2003; 63: 8118-21.
170. Dou, Q.P., Nam, S., Smith, D.M. Tea polyphenol esters and analogs thereof for cancer prevention and treatment. US6713506 (2004).
171. Zhang X, Zhang H, Tighiouart M, Lee JE, Shin HJ, Khuri FR, et al. Synergistic inhibition of head and neck tumor growth by green tea (-)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor. Int J Cancer 2008; 123: 1005-14.
172. Masuda M, Suzui M, Lim JT, Deguchi A, Soh JW, Weinstein IB. Epigallocatechin-3-gallate decreases VEGF production in head and neck and breast carcinoma cells by inhibiting EGFR-related pathways of signal transduction. J Exp Ther Oncol 2002; 2: 350-9.
173. Kitada S, Leone M, Sareth S, Zhai D, Reed JC, Pellecchia M. Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/ leukemia-2 proteins. J Med Chem 2003; 46: 4259-64.
174. Zhang M, Liu H, Guo R, Ling Y, Wu X, Li B, et al. Molecular mechanism of gossypol-induced cell growth inhibition and cell death of HT-29 human colon carcinoma cells. Biochem Pharmacol 2003; 66: 93-103.
175. Wang, S., Yang, D., Enyedy, I.J. Small molecule inhibitors targeted at Bcl-2. US7354928 (2008).
176. Wang, S., Yang, D., Xu, L. Small molecule antagonists of Bcl-2 family proteins. US20090092684 (2009).
177. Oliver CL, Bauer JA, Wolter KG, Ubell ML, Narayan A, O'Connell KM, et al. In vitro effects of the BH3 mimetic, (-)- gossypol, on head and neck squamous cell carcinoma cells. Clin Cancer Res 2004; 10: 7757-63.
178. Bauer JA, Trask DK, Kumar B, Los G, Castro J, Lee JS, et al. Reversal of cisplatin resistance with a BH3 mimetic, (-)-gossypol, in head and neck cancer cells: Role of wild-type p53 and Bcl-xL. Mol Cancer Ther 2005; 4: 1096-104.
179. Konac E, Ekmekci A, Yurtcu E, Ergun MA. An in vitro study of cytotoxic effects of gossypol on human epidermoid larynx carcinoma cell line (HEp-2). Exp Oncol 2005; 27: 81-3.
180. Wolter KG, Wang SJ, Henson BS, Wang S, Griffith KA, Kumar B, et al. (-)-gossypol inhibits growth and promotes apoptosis of human head and neck squamous cell carcinoma in vivo. Neoplasia 2006; 8: 163-72.
181. Boehm AL, Sen M, Seethala R, Gooding WE, Freilino M, Wong SM, et al. Combined targeting of epidermal growth factor receptor, signal transducer and activator of transcription-3, and Bcl-X(L) enhances antitumor effects in squamous cell carcinoma of the head and neck. Mol Pharmacol 2008; 73: 1632-42.
182. Hu ZY, Zhu XF, Zhong ZD, Sun J, Wang J, Yang D, et al. ApoG2, a novel inhibitor of antiapoptotic Bcl-2 family proteins, induces apoptosis and suppresses tumor growth in nasopharyngeal carcinoma xenografts. Int J Cancer 2008; 123: 2418-29.
183. Baumgrass R, Weiwad M, Erdmann F, Liu JO, Wunderlich D, Grabley S, et al. Reversible inhibition of calcineurin by the polyphenolic aldehyde gossypol. J Biol Chem 2001; 276: 47914-21.
184. Ford JM, Hait WN, Matlin SA, Benz CC. Modulation of resistance to alkylating agents in cancer cell by gossypol enantiomers. Cancer Lett 1991; 56: 85-94.
185. Yu Y, Deck JA, Hunsaker LA, Deck LM, Royer RE, Goldberg E, et al. Selective active site inhibitors of human lactate dehydrogenases A4, B4, and C4. Biochem Pharmacol 2001; 62: 81-9.
186. Stein RC, Joseph AE, Matlin SA, Cunningham DC, Ford HT, Coombes RC. A preliminary clinical study of gossypol in advanced human cancer. Cancer Chemother Pharmacol 1992; 30: 480-2.
187. Kim KM, Giedt CD, Basanez G, O'Neill JW, Hill JJ, Han YH, et al. Biophysical characterization of recombinant human Bcl-2 and its interactions with an inhibitory ligand, antimycin A. Biochemistry 2001; 40: 4911-22.
188. Schwartz PS, Manion MK, Emerson CB, Fry JS, Schulz CM, Sweet IR, et al. 2-Methoxy antimycin reveals a unique mechanism for Bcl-x(L) inhibition. Mol Cancer Ther 2007; 6: 2073-80.
189. Tzung SP, Kim KM, Basanez G, Giedt CD, Simon J, Zimmerberg J, et al. Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. Nat Cell Biol 2001; 3: 183-91.
190. Wang H, Li M, Rhie JK, Hockenbery DM, Covey JM, Zhang R, et al. Preclinical pharmacology of 2-methoxyantimycin A compounds as novel antitumor agents. Cancer Chemother Pharmacol 2005; 56: 291-8.
191. Chan SL, Lee MC, Tan KO, Yang LK, Lee AS, Flotow H, et al. Identification of chelerythrine as an inhibitor of BclXL function. J Biol Chem 2003; 278: 20453-6.
192. Cohen EE, Lingen MW, Zhu B, Zhu H, Straza MW, Pierce C, et al. Protein kinase C zeta mediates epidermal growth factor-induced growth of head and neck tumor cells by regulating mitogen-activated protein kinase. Cancer Res 2006; 66: 6296-303.
193. Weichselbaum RR, Kufe DW, Chmura SJ, Dolan ME. Chelerythrine-based therapies for cancer. US6426351 (2002).
194. Hoffmann TK, Leenen K, Hafner D, Balz V, Gerharz CD, Grund A, et al. Antitumor activity of protein kinase C inhibitors and cisplatin in human head and neck squamous cell carcinoma lines. Anticancer Drugs 2002; 13: 93-100.
195. Chmura SJ, Dolan ME, Cha A, Mauceri HJ, Kufe DW, Weichselbaum RR. In vitro and in vivo activity of protein kinase C inhibitor chelerythrine chloride induces tumor cell toxicity and growth delay in vivo. Clin Cancer Res 2000; 6: 737-42.
196. Enyedy IJ, Ling Y, Nacro K, Tomita Y, Wu X, Cao Y, et al. Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. J Med Chem 2001; 44: 4313-24.
197. Wang, S., Yang, D., Enyedy, I.J. Small molecule inhibitors targeted at Bcl-2. US6703382 (2004).
198. Sarma MD, Ghosh R, Patra A, Chowdhury R, Chaudhuri K, Hazra B. Novel glycoconjugates of diospyrin, a quinonoid plant product: synthesis and evaluation of cytotoxicity against human malignant melanoma (A375) and laryngeal carcinoma (Hep2). Org Biomol Chem 2007; 5: 3115-25.
199. Li R, Zang Y, Li C, Patel NS, Grandis JR, Johnson DE. ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway. Mol Pharmacol 2009; 75: 1231-9.
200. Ashimori N, Zeitlin BD, Zhang Z, Warner K, Turkienicz IM, Spalding AC, et al. TW-37, a small-molecule inhibitor of Bcl-2, mediates S-phase cell cycle arrest and suppresses head and neck tumor angiogenesis. Mol Cancer Ther 2009; 8: 893-903.
201. Qian, C., Cai, X., Zhai, H. Bcl-2 inhibitors containing a zinc binding moiety. WO2009036051 (2009).
202. Castro, A.C., Grogan, M.J., Holson, E.B., Hopkins, B.T., Koney, N.O., Peluso, S., Snyder, D.A. Compounds and methods for inhibiting the interaction of Bcl proteins with binding partners. US7745464 (2010).
203. Walensky, L.D., Stewart, M.L. Methods and compositions for specific modulation of MCL-1. WO2010068684 (2010).
204. Baell, J., Wei, A.H., Scanlon, D.B. Conjugates and Therapeutic uses thereof. US20070197430 (2007).
205. Li R, Boehm AL, Miranda MB, Shangary S, Grandis JR, Johnson DE. Targeting antiapoptotic Bcl-2 family members with cellpermeable BH3 peptides induces apoptosis signaling and death in head and neck squamous cell carcinoma cells. Neoplasia 2007; 9: 801-11.
206. Chen J, Freeman A, Liu J, Dai Q, Lee RM. The apoptotic effect of HA14-1, a Bcl-2-interacting small molecular compound, requires Bax translocation and is enhanced by PK11195. Mol Cancer Ther 2002; 1: 961-7.
207. Vogler M, Weber K, Dinsdale D, Schmitz I, Schulze-Osthoff K, Dyer MJ, et al. Different forms of cell death induced by putative BCL2 inhibitors. Cell Death Differ 2009; 16: 1030-9.
208. Attardo, G., Lavallee, J.F., Rioux, E., Doyle, T.W. Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases. US7425553 (2008).
209. Ziwei, H. Synthesis of 4H-chromene derivatives US6660871 (2003).
210. Sharma H, Sen S, Lo Muzio L, Mariggio A, Singh N. Antisense-mediated downregulation of anti-apoptotic proteins induces apoptosis and sensitizes head and neck squamous cell carcinoma cells to chemotherapy. Cancer Biol Ther 2005; 4: 720-7.
211. Zhang L, Wen HT, Wang LX, Zhang YH. Bcl-XL antisense oligodeoxynucleotide sensitizes human esophageal cancer cell line to 5-fluorouracil. Zhonghua Zhong Liu Za Zhi 2006; 28: 173-7.
212. Warrel, Jr. R.P. Methods of treatment of a Bcl-2 disorder using Bcl-2 antisense oligomers. US20050032714 (2005).
213. Frieden, M., Hansen, J.B., Orum, H., Westergaard, M., Thrue, C.A. Oligomeric compounds for the modulation of Bcl-2. US7622453 (2009).
214. Moreira JN, Santos A, Simoes S. Bcl-2-targeted antisense therapy (Oblimersen sodium): Towards clinical reality. Rev Recent Clin Trials 2006; 1: 217-35.
215. Lacy J, Loomis R, Grill S, Srimatkandada P, Carbone R, Cheng YC. Systemic Bcl-2 antisense oligodeoxynucleotide in combination with cisplatin cures EBV+ nasopharyngeal carcinoma xenografts in SCID mice. Int J Cancer 2006; 119: 309-16.
216. Marshall J, Chen H, Yang D, Figueira M, Bouker KB, Ling Y, et al. A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors. Ann Oncol 2004; 15: 1274-83.
217. Morris MJ, Cordon-Cardo C, Kelly WK, Slovin SF, Siedlecki K, Regan KP, et al. Safety and biologic activity of intravenous BCL-2 antisense oligonucleotide (G3139) and taxane chemotherapy in patients with advanced cancer. Appl Immunohistochem Mol Morphol 2005; 13: 6-13.
218. Morris MJ, Tong WP, Cordon-Cardo C, Drobnjak M, Kelly WK, Slovin SF, et al. Phase I trial of Bcl-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res 2002; 8: 679-83.
219. Rheingold SR, Hogarty MD, Blaney SM, Zwiebel JA, Sauk-Schubert C, Chandula R, et al. Phase I Trial of G3139, a Bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: A Children's Oncology Group Study. J Clin Oncol 2007; 25: 1512-8.
220. Tolcher AW. Targeting Bcl-2 protein expression in solid tumors and hematologic malignancies with antisense oligonucleotides. Clin Adv Hematol Oncol 2005; 3: 635-42, 62.
221. Skoda C, Erovic BM, Wachek V, Vormittag L, Wrba F, Martinek H, et al. Down-regulation of Mcl-1 with antisense technology alters the effect of various cytotoxic agents used in treatment of squamous cell carcinoma of the head and neck. Oncol Rep 2008; 19: 1499-503.
222. Reed, J.C., Harigai, M. Bcl-2 gene inhibitory element binding factor. US5643727 (1997).
223. Slack, F.J., Johnson, S.M., Grosshans, H., Weidhass, J.B. Regulation of oncogenes by microRNAs. US7741306 (2010).
224. Mcwiggen, J., Beigelman, L. RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (Bcl-2) gene expression using short interfering nucleic acid (siNA). US20050176025 (2005).
225. van Delft MF, Huang DC. How the Bcl-2 family of proteins interact to regulate apoptosis. Cell Res 2006; 16: 203-13.
226. Foreman KE, Wrone-Smith T, Boise LH, Thompson CB, Polverini PJ, Simonian PL, et al. Kaposi's sarcoma tumor cells preferentially express Bcl-xL. Am J Pathol 1996; 149: 795-803.
227. Hermine O, Haioun C, Lepage E, d'Agay MF, Briere J, Lavignac C, et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 1996; 87: 265-72.
228. Wilson JW, Nostro MC, Balzi M, Faraoni P, Cianchi F, Becciolini A, et al. Bcl-w expression in colorectal adenocarcinoma. Br J Cancer 2000; 82: 178-85.
229. Xing C, Wang L, Tang X, Sham YY. Development of selective inhibitors for anti-apoptotic Bcl-2 proteins from BHI-1. Bioorg Med Chem 2007; 15: 2167-76.